Eir Ventures

Moleculent is a biotechnology company focused on advancing human health through technology-enabled products that utilize insights into the molecular basis of human biology. The company is dedicated to decoding human biology and aims to significantly enhance therapies and diagnostics by leveraging new scientific knowledge. Moleculent believes that a deeper understanding of molecular mechanisms, especially in relation to health and disease, will emerge over the next decade, paving the way for innovative healthcare solutions. Through its efforts, the company seeks to provide healthcare professionals with access to molecular science-based therapies and diagnostics that can improve patient care and outcomes.

ArgusEye specializes in biotechnology sensor solutions. Its patented technology, based on nanoplasmonic sensing with fiber optics, enables real-time detection of biological systems and processes. By customizing receptors, ArgusEye offers flexible and sensitive sensing systems for diverse targets.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Henlez is a biotechnology company focused on developing innovative enzyme-based therapies for recurrent follicular skin disorders. The company utilizes precise enzymes to formulate effective and stable topical treatments aimed at managing conditions such as hidradenitis. By emphasizing safety and affordability, Henlez aims to provide patients with potent solutions for their dermatological issues.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Synklino is a biotechnology company specializing in the development of a cytomegalovirus (CMV)-specific immunotoxin aimed at eradicating CMV infections. This innovative immunotoxin is designed to effectively target and eliminate both lytic and latently infected cells, providing rapid relief from the virus. By ensuring fast and safe eradication of CMV infections, Synklino's solution enhances long-term survival prospects for transplant recipients, ultimately contributing to better overall health outcomes for patients undergoing transplantation. The company's focus on addressing CMV infections positions it as a key player in improving post-transplant care and patient quality of life.

Cinclus Pharma AG is a research-based biotech company focused on developing small molecules to treat gastric acid-related diseases, with a particular emphasis on gastroesophageal reflux disease (GERD). Their primary asset, X842, is designed to address severe erosive GERD and has undergone Phase I clinical trials. Additionally, the company is exploring a dual therapy treatment that combines an antibiotic targeting Helicobacter pylori bacteria. Cinclus Pharma AG operates from its headquarters in Basel, Switzerland.

Scenic Biotech develops genomics and immunotherapy technologies to unlock genetic suppressors as new drug targets for cancer and rare genetic diseases. The company focuses on disease suppressing genes that can counteract disease-causing mutations, enabling rapid identification and validation of novel targets for medicines. By leveraging genomics to identify modifiers that suppress or block the effects of harmful genes, Scenic Biotech aims to create disease-modifying therapies that address the genetic drivers of severe illnesses.

Strike Pharma specializes in personalized cancer treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC) technology. The company employs an antibody-based technique tailored to each patient's tumor genetic profile, selectively destroying tumor cells while minimizing harm to normal cells and reducing side effects. This approach aims to provide patients with affordable, effective treatment.

Synklino is a biotechnology company specializing in the development of a cytomegalovirus (CMV)-specific immunotoxin aimed at eradicating CMV infections. This innovative immunotoxin is designed to effectively target and eliminate both lytic and latently infected cells, providing rapid relief from the virus. By ensuring fast and safe eradication of CMV infections, Synklino's solution enhances long-term survival prospects for transplant recipients, ultimately contributing to better overall health outcomes for patients undergoing transplantation. The company's focus on addressing CMV infections positions it as a key player in improving post-transplant care and patient quality of life.